There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that have a direct impact on men with advanced prostate cancer. Today’s review is about how to create better results for [...]
An important update from the phase III PREVAIL study (Xtandi in the pre-chemotherapy stage) was released thsi evening (actually yesterday evening) in advance of a formal presentation this Thursday at ASCO GU. The news is good, no the news is great. Last November the trial of Xtandi in men with metastatic castrate resistant prostate cancer [...]
One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]
Men initially diagnosed with advanced prostate cancer often face a serious question, whether traditional primary treatments that would remove or make smaller their primary tumor (“debulking” the tumor) provide any advantage or extend their survival. Since the most commonly used method to debulk tumors is surgery or radiation the question becomes if the risks of [...]
According to an analysis led by the Duke Cancer Institute, tasquinimo, an investigational prostate cancer treatment slows disease progression and may also increase survival, especially among men whose cancer has spread to the bones. This study that was published on Nov. 19, 2013, in the journal Clinical Cancer Research, shows that long-term survival and safety [...]